Patents by Inventor Fiorenzo Refosco

Fiorenzo Refosco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220054663
    Abstract: The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99mTc(N)(PNP)]-based compound suitable for a kit formulation.
    Type: Application
    Filed: September 2, 2021
    Publication date: February 24, 2022
    Applicant: BRACCO IMAGING SPA
    Inventors: Cristina BOLZATI, Nicola SALVARESE, Fiorenzo REFOSCO, Simona GHIANI, Alessandro MAIOCCHI, Barbara SPOLAORE
  • Patent number: 11160886
    Abstract: The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: November 2, 2021
    Assignee: BRACCO IMAGING SPA
    Inventors: Cristina Bolzati, Nicola Salvarese, Fiorenzo Refosco, Simona Ghiani, Alessandro Maiocchi, Barbara Spolaore
  • Publication number: 20200078479
    Abstract: The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.
    Type: Application
    Filed: December 15, 2017
    Publication date: March 12, 2020
    Applicant: BRACCO IMAGING SPA
    Inventors: Cristina BOLZATI, Nicola SALVARESE, Fiorenzo REFOSCO, Simona GHIANI, Alessandro MAIOCCHI, Barbara SPOLAORE
  • Patent number: 8182789
    Abstract: A bisphosphonoamine compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: May 22, 2012
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Francesco Tisato, Fiorenzo Refosco, Cristina Bolzati, Stefania Agostini, Marina Porchia, Mario Cavazza-Ceccato, Shinji Tokunaga
  • Patent number: 7771704
    Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L1L2]+Z? wherein Me, R, L1L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium-or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me=N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me=N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me=N—R)L1L2]+ Z?heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: August 10, 2010
    Assignee: Bracco Imaging S.p.A.
    Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
  • Publication number: 20100160615
    Abstract: A bisphosphonoaminc compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.
    Type: Application
    Filed: January 20, 2006
    Publication date: June 24, 2010
    Applicant: NIHON MED-PHYSICS CO., LTD.
    Inventors: Francesco Tisato, Fiorenzo Refosco, Cristina Bolzati, Stefania Agostini, Marina Porchia, Mario Cavazza-Ceccato, Shinji Tokunaga
  • Patent number: 7445765
    Abstract: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a ? electron acceptor and a bidentate ligand as a ? electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: November 4, 2008
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
  • Publication number: 20080267869
    Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me=N—R)L1L2]+Z? (I), wherein Me, R, L1 L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me=N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me=N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me=N—R)L1L2]+ Z?heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    Type: Application
    Filed: June 23, 2008
    Publication date: October 30, 2008
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
  • Publication number: 20080267868
    Abstract: A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [99mTc(N)(PNP)(XY)]+. In this formula, 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand as described in the specification. The compound of the formula is markedly accumulated in heart and adrenal glands and hence is used for radiodiagnostic imaging of heart and adrenal glands.
    Type: Application
    Filed: August 9, 2007
    Publication date: October 30, 2008
    Applicant: Nihon Medi-Physics, Co., Ltd.
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
  • Patent number: 7396523
    Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me?N—R)L1L2]+Z (I), wherein Me, R, L1 L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me?N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me?N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me?N—R)L1L2]+Z? heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: July 8, 2008
    Assignee: Bracco Imaging S.p.A.
    Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
  • Publication number: 20060120957
    Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): [(Me?N—R)L1L2]+Z. (I), wherein Me, R, L1 L2 and Z? have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L1, which allows the formation of substitution-inert [(Me?N—R)L1] moieties. Such moieties are fixed in an intermediate [(Me?N—R)Y2L1)]+ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L2 to give the final [(Me?N—R)L1L2]+Z?heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L2 framework or the imido R group.
    Type: Application
    Filed: October 31, 2003
    Publication date: June 8, 2006
    Inventors: Francesco Tisato, Cristina Bolzati, Marina Porchia, Fiorenzo Refosco
  • Publication number: 20040018147
    Abstract: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a &pgr; electron acceptor and a bidentate ligand as a &pgr; electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.
    Type: Application
    Filed: September 4, 2003
    Publication date: January 29, 2004
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
  • Publication number: 20020048549
    Abstract: The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance.
    Type: Application
    Filed: July 16, 2001
    Publication date: April 25, 2002
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Fiorenzo Refosco, Francesco Tisato
  • Patent number: 6270745
    Abstract: The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance. The radioactive transition metal nitride heterocomplex of the present invention is represented by the following formula (I): (M≡N)XY  (I) wherein a radioactive transition metal M is radioactive technetium or radioactive rhenium, N is a nitrogen atom, X is a diphosphine compound or a diarsine compound, and Y is a bindentate ligand having a combination of electron-donating atoms.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: August 7, 2001
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Fiorenzo Refosco, Francesco Tisato